ESC 365 - Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry

ESC Professional Premium Access

Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry

Session: Contemporary management of hypertrophic cardiomyopathy

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor N. Maurizi (Lausanne, CH)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Niccolo' Maurizi

University Hospital of Lausanne, Lausanne (Switzerland)

1 presentation

0 follower

5 more presentations in this session

Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Sacubitril/valsartan for treatment of symptomatic non-obstructive hypertrophic cardiomyopathy: a randomised, controlled, phase II clinical trial (SILICOFCM)

Speaker: Doctor M. Tafelmeier (Regensburg, DE)

Efficacy of cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Speaker: Ms N. Felix (Cajazeiras, BR)

Outcomes in patients with hypertrophic cardiomyopathy developing left ventricular systolic dysfunction after septal reduction therapy

Speaker: Miss D. Bataiosu (Zurich, CH)

The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis

Speaker: Miss S. Lyu (Beijing, CN)

Access the full session

Contemporary management of hypertrophic cardiomyopathy

Speakers: Doctor N. Maurizi, Doctor P. Garcia-Pavia, Doctor M. Tafelmeier, Ms N. Felix, Miss D. Bataiosu...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by